Trial Profile
A Randomized Open Label Pilot Study of Clostridium Butyricum MIYAIRI 588 (CBM588) in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Clostridium butyricum M588 (Primary)
- Indications Clostridium infections; Diarrhoea; Gastrointestinal disorders; Infections
- Focus Adverse reactions
- 21 Feb 2024 Planned End Date changed from 24 Dec 2023 to 24 Dec 2024.
- 21 Feb 2024 Planned primary completion date changed from 24 Dec 2023 to 24 Dec 2024.
- 19 Feb 2023 Planned End Date changed from 24 Dec 2022 to 24 Dec 2023.